Mexico: The War for the Allopathic Medicament Market in Mexico

Who could have imagined the current situation of the allopathic medicament market in Mexico 4 years ago?

Approximately four years ago, a tripartite advertising war in the massive communication media took place between laboratories manufacturing allopathic medicaments, that is, innovative medicaments or patent-protected medicaments, laboratories manufacturing interchangeable generic medicaments (GI’s by their initials in Spanish language), and laboratories manufacturing generic or "similar" (look-alikes) medicaments. In this war, each part enhanced the advantages of their products, emphasizing particularly in their respective costs.

The struggle still persists, and this conflict is being taken to other spheres besides the commercial ambit. For instance, the company "Farmacia de Similares" (Similars Pharmacy), which sells medicaments from the "similar" category, has publicly denounced that the Federal Consumers Representative (PROFECO), the Mexican Institute of Industrial Property (MIIP) and the Ministry of Health (MOH) are acting against it, because on the one hand, the first two organizations have emitted resolutions ordering "Farmacia de Similares" to remove its advertising campaign slogan "the same but cheaper", because it is considered as unlawful competition. On the other hand, "Farmacia de Similares" argues that the MOH is pretending to eliminate it from the market by modifying the standards for governmental acquisitions, because now, the MOH will demand only patent-protected medicaments or interchangeable generic medicaments (GI’s), which satisfactorily approve with the standards of bioequivalency tests.

As it can be seen, this dispute between laboratories is turning more intense as interesting each time, if we take into account that the allopathic medicament market in México is within the first ten in the world, and that it is number one in Latin America. Hence, we do not have to say that too many economical interests are at stake.

Many may wonder why does this conflict exists; well, the answer goes as follows:

Before implementing the interchangeable generic medicament program (commercially designated as GI’s) in 1998, there were only innovative or patent-protected medicaments and generic or similar medicaments in the market.

In 1991, the World Health Organization (WHO) had recommended the Mexican Government implementing a program for interchangeable generic medicaments. It was until 1998, that the MOH reformed the General Health Law (GHL), establishing the basis for the Interchangeable Generic Medicament Program. Since then, all official agreements by which a pharmaceutical product is rendered susceptible to be incorporated to the Interchangeable Generic Medicaments Catalogue, are published in the Official Diary of the Federation.

An interchangeable generic (GI) medicament is a medicament containing the same active ingredient as well as the same pharmaceutical dosage form of the corresponding innovative or patent-protected medicament, having then equal effectiveness and concentration. It also utilizes the same via of administration. Besides, an interchangeable generic medicament is required to approve the standards of the interchangeability tests, which certify it as a pharmaceutically equivalent medicament to the innovative medicament, this GI then showing to be as effective and safe as the innovative medicament, but at a lower market price. One of the main features of a GI is that it must be released in the market once the patent of the innovative medicament is no longer in force.

Now then, the generic or similar medicaments have been in the pharmaceutics market since long ago, conforming, above all, the source of the Basic Chart of consumable resources for the Health Sector. One of the possible reasons this happened was that, well before the enactment of the Industrial Property Law (IPL) of 1991 which was amended in 1994, many inventions were considered as non-patentable, including all types of pharmaceutical and biotechnological inventions. Hence, there was no protection of property rights for innovative medicaments, and therefore, the innovative medicaments market was very reduced.

Thus, from the date said IPL of 1991 was enacted, a broad protection of property rights was totally available for said pharmaceutical and biotechnological inventions. Mexico then became one of the most promising markets in the international sphere for foreign research and development foreign laboratories, as this amendment of the Law allowed innovative medicaments to increase their presence in the national market.

On the other hand, at the same time the GI’s appeared in the market, "Farmacia de Similares" had an accelerated growth in most of the national territory, accompanied by a powerful advertising campaign in the massive media, which slogan wielded that "similars" are equal to the innovative medicaments, but cheaper, although their purity and effectiveness had been questioned by the Health Authorities.

As a response to the "similars" advertising campaign, the manufacturers of GI’s, and of innovative medicaments, initiated, independently, their own advertising campaign in order to work against the "similars" campaign, by making tacit comparisons of the therapeutic effect of said innovative and interchangeable medicaments compared with that of the similars.

Another factor that has played a fundamental role in this conflict is the Sanitary Regulation, which affects at least two actors of this conflict, since, on the one hand, the MOH grants sanitary registrations (marketing authorizations) to all medicaments, without considering if the innovative medicament is still protected under a valid patent, reason for which the interests of said innovative medicaments are affected. On the other hand, however, nor the GHL neither its Regulation consider a continuous renovation schedule for sanitary registrations issued a long time ago, which greatly affects the GI’s.

Delving a little more into the first mentioned aspect, we now will refer to the complain the foreign pharmaceutical laboratories have presented, in the sense that the Health Authorities should not grant the sanitary registration to a generic interchangeable medicament or to a similar medicament until the patent protecting the innovative medicament is due, so the IPL as the international treaties of which Mexico is a party, are respected. Nevertheless, the health authorities have not listened to said petition, arguing that patents are not in their area of competency.

Regarding the second above aspect, it is important to mention that if there is a third laboratory interested in releasing a generic medicament in the market, it can meet with the MOH purity and effectiveness requirements for a generic medicament only by showing any document that certifies said conditions. Said documents can be copies of the studies done originally by the research laboratory for the innovative medicament, which can be obtained via Internet from the Food and Drug Administration (FDA) in the USA.

But, what has caused this war between laboratories?

The advertising war initiated approximately 4 years ago, has originated a great amount of confusion in the public, mainly in the people with less economical resources, because they are filled with ads referring to the advantages of each of the medicament categories. These ads also enhance the differences in prices of one with respect to the others, a fact which is difficult to understand if people do not have the elements at hand in order to make a real comparison.

On the other hand, we can mention that there also is a great deal of ignorance between the medical sector, since there is an elevated number of medics who are not aware of the pharmacological and therapeutic difference between each one of the aforementioned categories of medicaments, independently of their price, fact which aggravates the situation if we consider that the medic is the ideal person to guide their patients and prescribe them the medicament which is the safest and the most effective, so the disorder lasts the least.

Viewing the problem through this optic, I consider that a great sector of the population requiring of medicaments, buy these only because of their low price, without considering the other facts.

Together with the problems mentioned above, it is important to mention that in Mexico, until now, a policy for protection against health risks in matter of medicaments has not been really instrumented, even though the Federal Commission for Protection against Health Risks (COFEPRIS) has been created. The above is completely evident, as there is not any health control or vigilance in stores or drugstores that sell medicaments, since a prescription is not required to buy them even though the label of the medicament quotes according to the law: "prescription is required for selling or supplying of this medicament", these medicaments becoming therefore, "free-access" medicaments. This fact contributes to self-medication in a considerable manner.

With this panorama, it is necessary to attack the problem from the root by giving in-depth solutions and not simply temporary or superficial remedies which partially alleviate the conflict. For that purpose, I consider that it is essential to define a medicament policy suitable to the globalization times we are living, promoting more legal safety and equity in the pharmaceutical sector.

To achieve the aforementioned, it is fundamental to amend the GHL and its Regulations, in order that the granting of the required sanitary registrations is subject to the dispositions of the IPL and to the International Treaties of which Mexico is a party, besides meeting with the requirements indicated in the applicable norm.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.